It is made available under a CC-BY 4.0 International license .

1 <u>Title:</u>

- 2 Trends in neural tube defects in Scotland 2000-2021 prior to the introduction of
- 3 mandatory folic acid fortification of non-wholemeal wheat flour: a population-based
- 4 study.
- 5

6 Author list:

- 7 Amir Kirolos¹, Rute Vieira^{1,2}, Clara Calvert^{1,3}, Emily Griffiths¹, Rachael Wood^{1,3}
- 8 1. Public Health Scotland, Edinburgh, Scotland, UK.
- 9 2. Institute of Applied Health Sciences, School of Medicine, Medical Sciences and
- 10 Nutrition, The University of Aberdeen, Aberdeen, Scotland.
- 11 3. Usher Institute, University of Edinburgh, Edinburgh, Scotland, UK
- 12
- 13 Corresponding author: Professor Rachael Wood (rachael.wood@phs.scot)
- 14

15 Abstract:

- 16 **Objective:** To describe the total birth prevalence of neural tube defects (NTDs) in Scotland
- 17 2000-2021.
- 18 **Design:** National, population-based study.
- 19 **Setting:** Scotland, UK.

20	Participants: Babies with an NTD and pregnancy outcome of live birth, stillbirth (≥20 weeks
21	gestation), or termination of pregnancy (any gestation), as recorded in the Scottish Linked
22	Congenital Condition Dataset.
23	Exposures: Year, maternal age group, maternal area-level deprivation quintile.
24	Main outcome measures: Total birth prevalence of all NTDs and, separately, anencephaly
25	and spina bifida (per 10,000 total births). The association between exposures and outcomes
26	was investigated using Poisson regression.
27	Results: In Scotland 2000-2021, there were 1,178 babies with a recorded NTD (436
28	anencephaly, 577 spina bifida) and 1,203,491 total births. Total birth prevalence of NTDs was
29	9.8 [95% CI 9.2, 10.4] per 10,000 total births. Prevalence was lower among babies to
30	mothers aged 30-39 years (compared to younger or older) and those from less (compared to
31	more) deprived areas. There was no evidence of change over the study period in prevalence
32	of NTDs (prevalence rate ratio [PRR] 1.01 [95% Cl 0.997, 1.02] p=0.16), or spina bifida (PRR
33	0.99 [95% CI 0.98, 1.01] p=0.35). The prevalence of anencephaly showed no change 2000-
34	2012, then increased 2013-2021 (PRR 1.12 [95% CI 1.06, 1.19] p<0.001).
35	Conclusions: Observed trends in anencephaly likely reflect increasing detection in early
36	pregnancy. Current strategies are failing to equitably reduce NTDs in Scotland. Monitoring of
37	future trends is needed to assess the impact of mandatory folic acid fortification.
38	

It is made available under a CC-BY 4.0 International license .

39 Summary:

40 What is already known on this topic

 Recommendations for volunta 	ry fortification of some foods, and for p	pre-conception
---	---	----------------

42 daily supplements of folic acid, have been in place since the 1980s and 1990s

43 respectively to support prevention of neural tube defects (NTDs).

- 44 Most women do not take folic acid supplements before conception, and uptake is
- 45 particularly low in younger mothers and those from poorer socioeconomic
- 46 backgrounds.
- 47 Legislation to mandate the fortification of non-wholemeal wheat flour with folic acid
- 48 was introduced in November 2024. This provides an opportunity to improve the

49 equitable prevention of NTDs.

50 What this study adds

- 51 There is no evidence that the total birth prevalence of NTDs in Scotland changed
- 52 2000-2021. Prevalence was lowest among mothers in the 30-39 year age group, and

53 those from less deprived areas.

- 54 There is no evidence that the total birth prevalence of spina bifida in Scotland
- changed 2000-2021, however the prevalence of anencephaly increased 2013-2021,
- 56 likely reflecting increasing early antenatal detection of this condition through
- 57 ultrasound scans.
- 58 How this study might affect research, practice, or policy

- 59 This study provides baseline information for the period before the introduction of
- 60 mandatory fortification. It will be used to support the evaluation of mandatory
- 61 fortification, and hence guide future policy development.

It is made available under a CC-BY 4.0 International license .

62 Introduction:

63	Neural tube defects (NTDs) (comprising anencephaly, spina bifida, and, least commonly,
64	encephalocele) are congenital conditions arising due to incomplete closure of the neural
65	tube during early fetal development(1). Pregnancies affected by an NTD are at increased risk
66	of miscarriage or stillbirth. Babies born with spina bifida have lifelong disabilities that can
67	include paraplegia, bladder and bowel dysfunction, hydrocephalus, and learning disabilities.
68	Anencephaly is incompatible with long term survival. The chance of having an affected
69	pregnancy increases with decreasing maternal levels of folate (vitamin B9) and there is well
70	established evidence that taking pre-conception supplements of folic acid (a synthetic form
71	of folate) reduces the risk of having an affected pregnancy(2-4).
72	There is evidence that the total birth prevalence (hereafter 'prevalence' for brevity) of NTDs
73	fell in the UK between the 1970s and 1990s then stabilised, linked to dietary improvements
74	and, from the mid-1980s onwards, the voluntary fortification of some breakfast cereals and
75	bread with folic acid(5). Daily folic acid supplements have also been recommended for
76	women who are planning, and in the first trimester of, pregnancy since 1992(6). However, a
77	study in England in 1999-2012 found only a third reported taking supplements before
78	conception(7). The uptake of supplements, and folate status, vary markedly by maternal
79	sociodemographic factors(8,9).
80	Mandatory folic acid fortification of various staple foods introduced in other countries has
81	been associated with a reduction in the prevalence of NTDs(10). Legislation to mandate the
82	fortification of non-wholemeal wheat flour (and hence all products containing this flour) in
83	the UK at a level of 250mcg per 100g was introduced in November 2024, for implementation
84	by end 2026(11). Recommendations on daily folic acid supplements (and the possibility of

It is made available under a CC-BY 4.0 International license .

- 85 additional voluntary fortification) remain unchanged. Modelling estimates this will lead to a
- 86 15-22% reduction in the prevalence of NTDs(12).
- 87 We aimed to examine secular trends in the prevalence of NTDs in Scotland 2000-2021.
- 88 Establishing these pre-implementation trends will support evaluation of the impact of
- 89 mandatory fortification and guide future policy decisions.
- 90

91 Methods:

- 92 Our study protocol is available at <u>https://publichealthscotland.scot/publications/trends-in-</u>
- 93 <u>neural-tube-defects-protocol/</u>. We followed STROBE reporting guidelines(13).

94 Data Sources

- 95 Scottish Linked Congenital Condition Dataset (SLiCCD)
- 96 SLiCCD includes all babies from pregnancies ending in Scotland 2000-2021 that were
- 97 recorded as having a major congenital condition on a relevant source dataset(14,15). Major
- 98 congenital conditions are defined as structural or chromosomal conditions meeting
- 99 EUROCAT inclusion criteria(16). Babies are included in SLiCCD if the pregnancy ends in a live
- 100 birth (any gestation, baby diagnosed before their first birthday), stillbirth (≥20 weeks
- 101 gestation), or termination of pregnancy (any gestation). SLiCCD is derived from the following
- national datasets: statutory live birth, stillbirth (≥24 weeks gestation), and infant (<1 year)
- 103 death registration records; statutory termination of pregnancy notifications; hospital
- 104 maternity, neonatal, and paediatric (<1 year) inpatient discharge records; and MBRRACE-UK
- 105 perinatal mortality surveillance records(17). Diagnostic codes on these source records are
- 106 examined to identify records indicating a relevant condition. All records relating to an

It is made available under a CC-BY 4.0 International license .

107	individual baby are then reconciled to provide personal identifiers; pregnancy end date and
108	outcome; sociodemographic variables including maternal age, maternal deprivation category
109	(Scottish Index of Multiple Deprivation (SIMD) quintile based on postcode of residence at
110	the end of pregnancy(18)), and infant sex; and the diagnostic codes indicating the congenital
111	condition(s) present(19). Each baby is allocated to one or more EUROCAT-defined condition
112	group (e.g., Nervous system conditions), level 1 subgroup (e.g., Neural tube defects), and
113	level 2 subgroup (e.g., Anencephaly, Encephalocele, Spina bifida) based on their diagnostic
114	codes. Babies with only non-specific codes available may be assigned to no groups, or to a
115	group but none of its subgroups. If a baby with an NTD has an underlying genetic condition,
116	that is flagged by also allocating them to the Genetic conditions group.
117	Congenital Conditions and Rare Diseases Registration and Information Service for Scotland
118	(CARDRISS) register
119	The CARDRISS register is a new, validated register of all babies with a major congenital
120	condition from pregnancies ending in Scotland 2021 onwards(20). It has the same inclusion
121	criteria as SLiCCD and uses the same source datasets, though CARDRISS uses a broader list of
122	codes to identify babies that may have a registerable condition. Trained registration staff
123	then access local clinical records to confirm whether a provisionally registered baby meets
124	inclusion criteria and, if so, complete their registration record, including de novo coding of all
125	congenital conditions present.

126 National Records of Scotland (NRS) live and stillbirths

127 Aggregate data on the number of registered live births (any gestation) and stillbirths (≥24

128 weeks gestation) were used as denominators to allow calculation of the total birth

- 129 prevalence of NTDs. Aggregate data was obtained for each year broken down by maternal
- 130 age group, maternal deprivation quintile, and infant sex.

131 Statistical analysis

- 132 Statistical analyses were conducted using R v4.1.2. Code is available at
- 133 https://github.com/Public-Health-Scotland/trends-in-ntds-public.
- 134 Number and total birth prevalence of NTDs
- 135 We used SLiCCD to report the total number of babies with an NTD from pregnancies ending
- 136 2000-2021 inclusive. We examined distribution by pregnancy outcome (live birth, stillbirth
- 137 [≥20 weeks], termination of pregnancy). In line with EUROCAT guidelines, we calculated the
- total birth prevalence ('prevalence') of NTDs per 10,000 total (registered live and still [≥24
- 139 weeks]) births overall, and by maternal age group and deprivation. Total birth prevalence is
- 140 the accepted proxy estimate of incidence of congenital conditions(21). We also calculated
- 141 the live birth prevalence of NTDs as the number of live born babies with an NTD per 10,000
- 142 live births, overall and by infant sex (which is only reliably recorded for live births).
- 143 Time trend analysis
- 144 We calculated the unadjusted prevalence of NTDs for each year with 95% confidence
- 145 intervals (CI) using Poisson (evidence of equidispersion of data) or Conway-Maxwell-Poisson
- 146 (COM-Poisson, evidence of over/underdispersion) regression models, fitted with year as the
- 147 exposure. We fitted two models: a) assuming a linear trend over time and b) using restricted
- 148 cubic splines assuming a non-linear trend over time; and selected the best-fitting model
- 149 using the Akaike Information Criteria (AIC).

150 If the model with a linear trend was chosen, we reported the unadjusted prevalence rate 151 ratio (uPRR) for year (PRR for year estimates the average annual percentage change in 152 prevalence) for the whole study period. If the model with a non-linear trend was chosen, we 153 used visual inspection of plots to divide the study period into sequential sub-periods, each 154 with a linear trend. We then used piecewise regression models to calculate the uPRRs for 155 year for each sub-period.

156 Sociodemographic factors

157 We used Poisson or COM-Poisson models to calculate uPRRs for the association between

158 prevalence of NTDs and, separately, maternal age and deprivation. To provide adjusted PRRs

159 (aPRRs) for these associations, we extended each model to include year as an exposure

160 (Models 1 and 2). Finally, we fitted a model including maternal age, deprivation, and year as

161 exposures (Model 3). Models assumed a linear or non-linear time trend as per findings in

the time trend analyses. Babies with missing data for maternal age and deprivation were

163 dropped from models including these variables.

164 If the time trend analysis showed a linear trend, models 1-3 were also used to provide the 165 aPRR for year adjusted for maternal age, deprivation, and both factors respectively. If the 166 time trend analysis showed a non-linear trend, aPRRs for year for each sub-period were not 167 provided as the relationship between the sociodemographic factors and prevalence may 168 vary across the sub-periods making the aPRRs difficult to interpret.

169 All analyses were repeated for the two most common sub-types of NTDs (anencephaly and

170 spina bifida) and for NTDs without an associated genetic condition (as NTDs in babies with

an associated genetic condition are less preventable by folate supplementation(22)).

It is made available under a CC-BY 4.0 International license .

172 Validation of SLiCCD against CARDRISS

173	We used data from the crossover period in 2021 to calculate the positive predictive value
174	(PPV) and sensitivity of recording of babies with NTDs in SLiCCD compared to CARDRISS(20).
175	PPV was the percentage of babies with an NTD included in SLiCCD that were also recorded
176	as having an NTD in CARDRISS. Sensitivity was calculated as the percentage of babies with an
177	NTD included in CARDRISS that were also recorded as having an NTD in SLiCCD. Analyses
178	were repeated for anencephaly, spina bifida, and NTDs without an associated genetic
179	condition.
180	Power to detect a 20% reduction in the prevalence of NTDs
181	As CARDRISS rather than SLiCCD will be used for prospective evaluation of the impact of
182	mandatory fortification, we calculated the prevalence of NTDs based on CARDRISS data for
183	2021. We assumed this prevalence and number of births would be the same for 2022-2024
184	to give us our pre-implementation data (CARDRISS data for 2022 onwards is not yet
185	available). We then calculated the power we would have to detect a 20% reduction in the
186	prevalence of NTDs(12,23) based on the cumulative number of births that would occur in the
187	10 years following full implementation of mandatory fortification. For this power calculation,
188	we assumed the annual number of births for these 10 years would remain the same as 2021
189	throughout, and that the 20% reduction occurred in the first year and then did not change.
190	Patient and Public involvement
191	We consulted with stakeholders including Spina Bifida Hydrocephalus Scotland to inform
192	study design and interpretation.

193

It is made available under a CC-BY 4.0 International license .

194 <u>Results:</u>

195 Number and total birth prevalence of NTDs

- 196 A total of 1,178 babies with an NTD and pregnancy end date 2000-2021 were included in
- 197 SLiCCD, of which 436 (37%) had anencephaly, 165 (14%) encephalocele, and 577 (49%) spina
- bifida (Table 1). There were 1,203,491 total births in 2000-2021, giving a prevalence of NTDs
- 199 of 9.8 [95% CI 9.2, 10.4] per 10,000 total births. Prevalence per 10,000 total births was 3.6
- 200 [95% CI 3.3, 4.0] for an encephaly, 1.4 [95% CI 1.2, 1.6] for encephalocele, and 4.8 [95% CI
- 4.4, 5.2] for spina bifida. Of the 1,178 babies with an NTD, 1,118 (95%) did not have an
- associated genetic condition (Supplementary Table 1). Overall, 35% (414) of the 1,178 babies
- with an NTD were live births. Pregnancy outcomes varied across the subtypes of NTD, with
- 204 8% (33) of babies with an encephaly and 53% (307) with spina bifida being live births.
- 205 The prevalence of NTDs was lower in maternal age groups 30-34 years and 35-39 years (8.6
- 206 [95% CI 7.7, 9.6] and 7.5 [95% CI 6.3, 8.7] per 10,000 total births respectively) compared to
- 207 younger and older age groups (Table 2). Similar patterns were observed for anencephaly,
- spina bifida, and NTDs without an associated genetic condition (Supplementary Table 2). The
- 209 prevalence of NTDs was lower in the two least deprived SIMD quintiles compared to other
- 210 quintiles (8.6 [95% CI 7.4, 9.9] and 8.5 [95% CI 7.3, 9.9] per 10,000 total births in quintiles 4
- and 5 respectively) (Table 2). Similar patterns were seen for spina bifida and NTDs without
- an associated genetic condition, though not for anencephaly (Supplementary Table 2). The
- 213 live birth prevalence of NTDs, and of each NTD subtype, was lower in male compared to
- 214 female live births (Table 2 and Supplementary Table 2).

215 NTD time trends and association with sociodemographic factors

It is made available under a CC-BY 4.0 International license .

216	Figure 1 shows the observed annual prevalence and unadjusted model estimates for NTDs,
217	anencephaly, and spina bifida 2000-2021. No time trend (linear or non-linear) was identified
218	in the prevalence of NTDs (uPRR for year 1.01 [95% CI 0.997, 1.02] p=0.16) (Table 3). For
219	anencephaly, we found evidence of a non-linear time trend: there was no evidence of a
220	change in prevalence 2000-2012 (uPRR 1.01 [95% CI 0.98, 1.04] p=0.64), then evidence of an
221	increase 2013-2021 (uPRR 1.12 [95% Cl 1.06, 1.19] p<0.001) (Supplementary Table 3). No
222	time trend was identified in the prevalence of spina bifida (uPRR 0.99 [95% CI 0.98, 1.01]
223	p=0.35) (Supplementary Table 4) or NTDs without an associated genetic condition
224	(Supplementary Figure 1 and Supplementary Table 5).
225	Table 3 shows associations between maternal age and deprivation and the prevalence of
226	NTDs. There was evidence that mothers aged 30-34 and 35-39 years old had lower aPRRs
227	compared to those aged 25-29 years when adjusted for both maternal deprivation and year.
228	There was no evidence of differences in aPRRs comparing each SIMD quintile to the least
229	deprived quintile when adjusted for maternal age and year.
230	The time trend in the prevalence of NTDs did not change after adjusting for maternal age
231	and deprivation in multivariable models (aPRR for year 1.01 [95% CI 0.999, 1.02] p=0.09).
232	Validation of SLiCCD
233	Table 4 shows the number of babies with an NTD recorded in SLiCCD and/or CARDRISS in
234	2021. 47 of the 48 babies recorded in SLiCCD with an NTD were confirmed in CARDRISS as
235	having an NTD, giving a PPV of 98% [95% CI 89, 100]. Of the 69 babies with an NTD recorded

- in CARDRISS, 47 were recorded as having an NTD in SLiCCD, giving a sensitivity of 68% [95%
- 237 CI 56, 79]. Of the 22 babies that were not recorded as having an NTD in SLiCCD, 20 were
- included in SLiCCD in some capacity, with 12 allocated to the Nervous system condition

It is made available under a CC-BY 4.0 International license .

- group, but no Neural tube defect subgroup. 19 of the 22 babies had termination of
- 240 pregnancy as their pregnancy outcome. PPV and sensitivity of SLiCCD compared to
- 241 CARDRISS was similar for all subtypes of NTDs (Supplementary Tables 6-8).
- 242 Power to detect a 20% reduction in the total birth prevalence of NTDs
- 243 For 2021, the prevalence of NTDs estimated from CARDRISS was 14.3 [95% CI 11.1, 18.1] per
- 244 10,000 total births. Based on this, seven years of cumulative data after full implementation
- of mandatory fortification will be required to reliably (i.e., with power of at least 80%) detect
- a 20% reduction in the prevalence of NTDs (Supplementary Table 9).
- 247

248 Discussion:

- 249 Our national, population-based study found no evidence of a change in the total birth
- 250 prevalence of NTDs in Scotland 2000-2021. We also found no evidence of a change in the
- 251 prevalence of spina bifida, or NTDs without an associated genetic condition, over this
- 252 period. For anencephaly, there was no change 2000-2012, then a 12% average annual
- increase in prevalence 2013-2021. We found that the prevalence of NTDs was lower among
- babies to mothers aged 30-39 years (compared to younger or older) and to mothers from
- 255 less (compared to more) deprived areas. The finding for maternal age persisted in
- 256 multivariable analyses, however adjusting for maternal age and deprivation did not change
- 257 our findings relating to trends over time.

258 Our study had strengths and limitations. We provide national, population-based data for a

- 259 22-year period with consistent policy on NTD prevention (voluntary fortification of some
- 260 foods and daily folic acid supplements). We estimate the associations between NTD

It is made available under a CC-BY 4.0 International license .

261 prevalence and maternal age and deprivation, and time trends in NTD prevalence, both

- 262 unadjusted and adjusted for these key sociodemographic factors.
- 263 We used a consistent data source (SLiCCD) and validate the most recent year's data against 264 Scotland's new, validated congenital condition register (CARDRISS) for transparency. The high 265 PPV of SLICCD compared to CARDRISS suggests we can have high confidence that babies 266 included in our analysis were correctly categorised as having an NTD. There are known 267 limitations in the clinical coding on source national datasets relating to terminations of 268 pregnancy, leading to under-ascertainment of babies with an NTD and this pregnancy 269 outcome in SLICCD compared to CARDRISS. The total birth prevalence of NTDs based on 270 SLICCD data that we report is therefore likely to be an underestimate of the true prevalence. 271 However, as there is no evidence of any change in the quality of termination data over time, 272 the trends we observe, and our overall interpretation of results, are likely to be valid. 273 Our results align with a recent study assessing trends in the prevalence of NTDs in England 274 2000-2019(24). While this study found evidence of a small increase in the prevalence of 275 NTDs over the study period, this was explained by an increase in anencephaly 2015-2019. 276 We also found an increase in anencephaly over the similar period 2013-2021. Our results 277 also align with those from an earlier study which found no change in the prevalence of NTDs 278 without an associated genetic condition in Europe 2003-2011, using data from 28 EUROCAT 279 registries in 19 European countries, including Wales and parts of England(25). 280 The prevalence of the different subtypes of NTDs would be expected to show similar trends 281 over time(24,25), hence the recent increase in prevalence of anencephaly, but not spina 282 bifida, seen in our results (and in England) is surprising. We cannot exclude that the increase
 - in an encephaly is real (particularly given evidence that population folate status has

It is made available under a CC-BY 4.0 International license .

284	worsened 2008-2019, the most recent period for which data is available(9)), or due to
285	changes in data quality. However, given the high spontaneous loss rate of pregnancies
286	affected by anencephaly, we suggest the most likely explanation is increasing ascertainment
287	of affected babies in early pregnancy followed by termination of a (diagnosed) pregnancy
288	rather than miscarriage of an (undiagnosed) pregnancy. Policy interventions from the early
289	2010s have promoted booking for antenatal care at earlier gestations, and a change in the
290	method of pregnancy screening for Down's syndrome from second trimester serum
291	screening to first trimester combined screening, implemented in Scotland from 2011, has
292	also promoted earlier ultrasound scanning(26,27).
293	We found differences in the prevalence of NTDs by sociodemographic factors, in particular
294	maternal age. There is evidence of marked inequalities in the uptake of pre-conception folic
295	acid supplements, with uptake particularly poor in younger women(28), and this may partly
296	explain our findings. Mandatory fortification offers an opportunity to more effectively and
297	equitably reduce the prevalence of NTDs, compared to the policy of voluntary fortification
298	and supplements in place during our study period, although there is debate over whether
299	the planned scope and level of fortification is sufficient(23,29).
300	Overall, this study shows that the prevalence of NTDs in Scotland 2000-2021 showed no
301	change, and inequalities in prevalence by maternal age were evident. This study will be used
302	to inform the evaluation of mandatory folic acid fortification of non-wholemeal wheat flour

303 in the UK, and hence to guide future public health policy in this and other settings.

It is made available under a CC-BY 4.0 International license .

304 Data availability statement

- 305 Subject to governance approvals, researchers can access pseudonymised extracts of datasets
- 306 used in this study through the Scottish NHS safe haven facility supported by Public Health
- 307 Scotland. Interested researchers should submit an initial enquiry form to Research Data
- 308 Scotland (<u>https://www.researchdata.scot/accessing-data/</u>).

309 Ethics Statements

- 310 Patient consent for publication
- 311 Not applicable

312 Ethics approval

- 313 This study involved the secondary analysis of routinely collected data and approval by an
- 314 ethics committee was not required as informed by the NHS Health Research Authority and
- 315 Public Health Scotland research risk assessment checklists. A Data Protection Impact
- 316 Assessment for this study was approved by the PHS Data Protection Officer (DP22230101).

317 Acknowledgements

- 318 We acknowledge the contribution of the CARDRISS analyst team within Public Health
- 319 Scotland in providing relevant data extracts.
- 320 We acknowledge the contribution of our stakeholder group, including representatives from
- 321 Scottish Government, Food Standards Scotland, the NHS Scotland paediatric neurosurgery
- 322 service, and Spina Bifida Hydrocephalus Scotland, to study design and interpretation. The
- 323 study team had final responsibility for study methodology and interpretation of results.

324 Contributions

It is made available under a CC-BY 4.0 International license .

- 325 AK, RV, CC, and RW designed the study. AK, RV, CC, and EG conducted the analyses. AK
- 326 drafted the manuscript, and all authors reviewed and contributed to its writing. All authors
- 327 had access to the data.

328 Funding

- 329 The authors have not declared a specific grant for this research from any funding agency in
- 330 the public, commercial, or not-for-profit sectors.

331 Completing interests

332 None declared.

It is made available under a CC-BY 4.0 International license .

333 <u>References</u>

- 334 (1) Stevenson RE. Brain and spinal cord. In: Stevenson RE, Hall JG, Everman DB, Solomon BD,
- editors. Oxford Monographs on Medical Genetics: Human Malformations and Related
- Anomalies. Third edition. Oxford: Oxford University Press; 2016. p. 385-402.
- (2) Wald N, Law M, Morris J, Wald D. Quantifying the effect of folic acid. The Lancet (British
 edition) 2001 Dec 15;358(9298):2069–2073.
- 339 (3) Prevention of neural tube defects: results of the Medical Research Council Vitamin
- 340 Study. MRC Vitamin Study Research Group. Lancet 1991 Ju;338(8760):131–137.
- 341 (4) Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by
- periconceptional vitamin supplementation. New England Journal of Medicine 1992 Dec
 24;327(26):1832–1835.
- 344 (5) Murphy M, Whiteman D, Stone D, Botting B, Schorah C, Wild J. Dietary folate and the
- 345 prevalence of neural tube defects in the British Isles: the past two decades. BJOG : an
- international journal of obstetrics and gynaecology 2000 Ju;107(7):885–889.
- (6) Busby A, Abramsky L, Dolk H, Armstrong B. Preventing neural tube defects in Europe:
 population based study. BMJ 2005 Mar 12;330(7491):574–575.
- 349 (7) Bestwick JP, Huttly WJ, Morris JK, Wald NJ. Prevention of Neural Tube Defects: A Cross-
- Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women.
 PLoS ONE 2014 Feb 19;9(2):e89354.
- (8) Shi Y, De Groh M, MacFarlane AJ. Socio-demographic and lifestyle factors associated with
 folate status among non-supplement-consuming Canadian women of childbearing age. Can J
 Public Health 2014 May 9;105(3):166.
- (9) Public Health England. NDNS: results from years 9 to 11 (2016 to 2017 and 2018 to
- 356 2019). 2020; Available at: https://www.gov.uk/government/statistics/ndns-results-from-
 357 years-9-to-11-2016-to-2017-and-2018-to-2019.
- (10) Crider KS, Qi YP, Yeung LF, Mai CT, Zauche LH, Wang A, et al. Folic Acid and the
 Prevention of Birth Defects: 30 Years of Opportunity and Controversies. ANNUAL REVIEW OF
 NUTRITION 2022;42:423–452.
- 361 (11) UK government. The Bread and Flour (Amendment) (England) Regulations 2024. 2024;
 362 Available at: <u>https://www.legislation.gov.uk/uksi/2024/1162/made.</u> Accessed Nov 21, 2024.
- 363 (12) Mayer C, Craig L, Horgan G. Stochastic modelling to estimate the potential impact of
 364 fortification of flour with folic acid in the UK. Food Standards Scotland 2017 Jul 31.

- 365 (13) von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al.
- 366 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
- 367 guidelines for reporting observational studies. BMJ 2007 Oct 20;335(7624):806–808.
- 368 (14) Information Services Division Scotland. Congenital anomalies in Scotland: 2012-2017.
 369 2019; Available at:
- 370 https://webarchive.nrscotland.gov.uk/20231129160814/https://www.isdscotland.org/Healt
- 371 <u>h-Topics/Maternity-and-Births/Publications/.</u> Accessed Oct 16, 2024.
- 372 (15) Public Health Scotland. Congenital conditions in Scotland: 2000 to 2021. 2023; Available
- at: https://publichealthscotland.scot/publications/congenital-conditions-in-
- 374 <u>scotland/congenital-conditions-in-scotland-2000-to-2021/.</u> Accessed Oct 16, 2024.
- 375 (16) EUROCAT. Guidelines for data registration. Available at: <u>https://eu-rd-</u>
- 376 platform.jrc.ec.europa.eu/eurocat/data-collection/guidelines-for-data-registration_en.
- **377** Accessed Aug 4, 2024.
- 378 (17) MBRRACE-UK. MBRRACE-UK: Mothers and Babies: Reducing Risk through Audits and
- 379 Confidential Enquiries across the UK. Available at: <u>https://www.npeu.ox.ac.uk/mbrrace-uk.</u>
 380 Accessed Nov 21, 2024.
- 381 (18) The Scottish Government. Scottish Index of Multiple Deprivation 2020. Available at:
- 382 <u>https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020/.</u> Accessed
 383 Oct 16, 2024.
- 384 (19) National datasets: Scottish Linked Congenital Conditions Dataset (SLiCCD). Available at:
- 385 <u>https://publichealthscotland.scot/services/national-data-catalogue/national-datasets/a-to-</u>
- 386 <u>z-of-datasets/scottish-linked-congenital-conditions-dataset-sliccd/.</u> Accessed 01 Ma, 2024.
- 387 (20) PHS. Congenital Conditions and Rare Diseases Registration and Information Service for
- 388 Scotland (CARDRISS). Available at: https://publichealthscotland.scot/our-areas-of-
- 389 work/disease-registration-and-screening/disease-registration/congenital-conditions-and-
- **390** <u>rare-diseases-registration-and-information-service-for-scotland-cardriss/overview/.</u>
- 391 (21) Mason CA, Kirby RS, Sever LE, Langlois PH. Prevalence is the preferred measure of
 392 frequency of birth defects. Birth Defects Res A Clin Mol Teratol 2005 Oc;73(10):690–692.
- 393 (22) Au KS, Ashley-Koch A, Northrup H. Epidemiologic and genetic aspects of spina bifida
 394 and other neural tube defects. Developmental Disabilities Research Reviews 2010;16(1):6–
 395 15.
- 396 (23) Morris JK, Addor M, Ballardini E, Barisic I, Barrachina-Bonet L, Braz P, et al. Prevention
 397 of Neural Tube Defects in Europe: A Public Health Failure. Front Pediatr 2021 Jun
 398 24;9:647038.
- (24) Broughan JM, Martin D, Higgins T, Swan G, Cullum A, Kurinczuk JJ, et al. Prevalence of
 neural tube defects in England prior to the mandatory fortification of non-wholemeal wheat

401 flour with folic acid: a population-based cohort study. Archives of disease in childhood 2024
402 Fe;109:106–112.

403 (25) Khoshnood B, Loane M, de Walle H, Arriola L, Addor M, Barisic I, et al. Long term trends
404 in prevalence of neural tube defects in Europe: population based study. BMJ 2015 Nov
405 24;351:h5949.

406 (26) Scottish Government. NHS Scotland performance against LDP standards. 2022;

407 Available at: <u>https://www.gov.scot/publications/nhsscotland-performance-against-ldp-</u>

408 <u>standards/pages/early-access-to-antenatal-services/.</u> Accessed Nov 21, 2024.

409 (27) Scottish Government. Changes to the pregnancy and newborn screening programmes.

- 410 2008; Available at: <u>https://www.publications.scot.nhs.uk/files/cel2008-31.pdf</u>.
- 411 (28) Health and Social Care Information Centre, IFF Research. Infant Feeding Survey UK,
- 412 2010. 2012 Nov 20.

413 (29) Wald N. Folic acid fortification: will the new UK government pass the "acid test"? BMJ
414 2024;385:q1286.

415

	Number (%) of babies with a recorded NTD	Number of total (<i>or live</i>) births	Total* (<i>or live†</i>) birth prevalence per 10,000 total (<i>live</i>) births (95% CI)
All NTDs	1,178	1,203,491	9.8 (9.2, 10.4)
Live birth	414 (35%)	1,197,700	3.5 (3.1, 3.8)
Stillbirth (≥20 weeks)	49 (4%)		
Termination of pregnancy	715 (61%)		
Anencephaly	436	1,203,491	3.6 (3.3, 4.0)
Live birth	33 (8%)	1,197,700	0.3 (0.2, 0.4)
Stillbirth (≥20 weeks)	32 (7%)		
Termination of pregnancy	371 (85%)		
Encephalocele	165	1,203,491	1.4 (1.2, 1.6)
Live birth	74 (45%)	1,197,700	0.6 (0.5, 0.8)
Stillbirth (≥20 weeks)	4 (2%)		
Termination of pregnancy	87 (53%)		
Spina bifida	577	1,203,491	4.8 (4.4, 5.2)
Live birth	307 (53%)	1,197,700	2.6 (2.3, 2.9)
Stillbirth (≥20 weeks)	13 (2%)		
Termination of pregnancy	257 (45%)		

مانست ما ام 1 ا بد : 1 2000 2021

*The total birth prevalence is calculated as the total number of babies with a recorded NTD divided by the total number of births (live and stillbirths) The live birth prevalence is calculated as the total number of liveborn babies with a recorded NTD divided by the total number of live births

	Number (%) of babies (<i>or live births</i>) with a recorded NTD	Number (%) of total (<i>or live</i>) births	Total* (or <i>live†</i>) birth prevalence per 10,000 total (<i>live</i>) births (95% CI)
Maternal age (years)			
<20	72 (6%)	69,567 (6%)	10.3 (8.1, 13.0)
20-24	242 (21%)	202,009 (17%)	12.0 (10.5, 13.6)
25-29	345 (29%)	318,696 (26%)	10.8 (9.7, 12.0)
30-34	312 (26%)	362,920 (30%)	8.6 (7.7, 9.6)
35-39	151 (13%)	202,487 (17%)	7.5 (6.3, 8.7)
≥40	50 (4%)	43,189 (4%)	11.6 (8.6, 15.3)
Unknown [‡]	6 (1%)	4,623 (<1%)	-
Maternal deprivation status			
SIMD quintile 1 - most deprived	316 (27%)	300,661 (25%)	10.5 (9.4, 11.7)
SIMD quintile 2	261 (22%)	247,983 (21%)	10.5 (9.3, 11.9)
SIMD quintile 3	228 (19%)	223,307 (19%)	10.2 (8.9, 11.6)
SIMD quintile 4	192 (16%)	223,729 (19%)	8.6 (7.4, 9.9)
SIMD quintile 5 - least deprived	175 (15%)	205,286 (17%)	8.5 (7.3, 9.9)
Unknown [‡]	6 (1%)	2,525 (<1%)	-
Infant sex [§]			
Male	203 (49%)	614,369 (51%)	3.3 (2.9, 3.8)
Female	211 (51%)	583,310 (49%)	3.6 (3.1, 4.1)
Unknown [‡]	0	21 (<1%)	-

. .

The total birth prevalence is calculated as the total number of babies with a recorded NTD divided by the total number of births (live and stillbirths) †The live birth prevalence is calculated as the total number of liveborn babies with a recorded NTD divided by the total number of live births ^{}Total or livebirth prevalence was not calculated for groups with missing sociodemographic data as it would be misleading if patterns of missingness differed in the numerator and (unlinked) denominator data

[§]Information on infant sex is shown for live births only as sex is often unknown for babies with an NTD where the pregnancy ended in early stillbirth or termination of pregnancy

			Model 1*		Model 2†		Model 3 [‡]	
	Unadjusted PRR (95% CI)	p value	Adjusted PRR (95% Cl)	p value	Adjusted PRR (95% CI)	p value	Adjusted PRR (95% Cl)	p value
Maternal age (years)								
<20	0.96 (0.75, 1.24)	0.76	0.98 (0.76, 1.26)	0.86			0.97 (0.75, 1.25)	0.81
20-24	1.11 (0.94, 1.30)	0.22	1.11 (0.94, 1.31)	0.20			1.11 (0.94, 1.31)	0.23
25-29	(ref)		(ref)				(ref)	
30-34	0.79 (0.68, 0.93)	0.003	0.79 (0.68, 0.93)	0.003	_		0.81 (0.69, 0.95)	0.01
35-39	0.69 (0.57, 0.84)	<0.001	0.69 (0.57, 0.83)	<0.001			0.71 (0.58, 0.86)	<0.001
≥40	1.08 (0.80, 1.45)	0.62	1.07 (0.80, 1.44)	0.64			1.11 (0.82, 1.49)	0.51
Maternal deprivation status								
SIMD quintile 1 - most deprived	1.23 (1.02, 1.48)	0.03			1.23 (1.02, 1.48)	0.03	1.10 (0.91, 1.34)	0.31
SIMD quintile 2	1.23 (1.02, 1.49)	0.03			1.23 (1.02, 1.49)	0.03	1.12 (0.92, 1.36)	0.25
SIMD quintile 3	1.20 (0.98, 1.46)	0.07			1.20 (0.98, 1.46)	0.08	1.12 (0.92, 1.37)	0.25
SIMD quintile 4	1.01 (0.82, 1.23)	0.95			1.00 (0.82, 1.23)	0.97	0.96 (0.78, 1.18)	0.72
SIMD quintile 5 - least deprived	(ref)				(ref)		(ref)	
Year (2000 to 2021)								
Average annual change	1.01 (0.997, 1.02)	0.16	1.01 (0.998, 1.02)	0.12	1.01 (0.998, 1.02)	0.12	1.01 (0.999, 1.02)	0.09

Table 3: Prevalence rate ratios (PRRs) for neural tube defects (NTDs), Scotland 2000-2021

PRR: Prevalence Rate Ratio; CI: Confidence Interval; SIMD: Scottish Index of Multiple Deprivation

*Model 1 is a multivariable model including maternal age and year

†Model 2 is a multivariable model including maternal deprivation status and year

^{*}Model 3 is a multivariable model including maternal age, maternal deprivation status, and year

Models 1-3 assume the trend of total birth prevalence of NTDs over time is linear

Table 4: Babies recorded as having	g an NTD in SLiCCD and the	e CARDRISS register, Scotland 2021

		CARDRISS register		
		Recorded as NTD	Not recorded as NTD	Total
	Recorded as NTD	47	1	48
SLiCCD	Not recorded as NTD	22		
	Total	69		

CARDRISS: Congenital conditions and rare diseases registration and information service for Scotland SLiCCD: Scottish linked congenital condition dataset

Figure 1: Observed and model-estimated annual total birth prevalence of all neural tube defects (NTDs), anencephaly and spina bifida, Scotland 2000-2021

